Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Blood (2024) 144 (12): 1284–1289.

https://doi.org/10.1182/blood.2023023639

Published: 2024

Includes: Supplemental data

Journal Articles

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Blood (2023) 142 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2023-182874

Published: 2023

Journal Articles

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Ashley Zimmerman, Keisha Heslop, Dustin Chapin, Taimur Sher, Vivek Roy, Ahsan Rasheed, Aneel Paulus, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 9331–9332.

https://doi.org/10.1182/blood-2022-165377

Published: 2022

Journal Articles

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Taimur Sher, Aneel Paulus, Dustin Chapin, Keisha Heslop, Asher Chanan-Khan, Vivek Roy

Blood (2022) 140 (Supplement 1): 4450–4451.

https://doi.org/10.1182/blood-2022-164656

Published: 2022

Journal Articles

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Sikander Ailawadhi, Ricardo D Parrondo, Aneel Paulus, Betsy Laplant, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Taimur Sher, Vivek Roy, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 9904–9905.

https://doi.org/10.1182/blood-2022-164667

Published: 2022

Journal Articles

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Sikander Ailawadhi, Ricardo D Parrondo, Gabriela Perez, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Ernesto Ayala, Patrick J O'Brien, Vivek Roy, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Stephanie Lanier, Carly Kasik, Schannon Bradley, Taimur Sher, Aneel Paulus, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 10165–10166.

https://doi.org/10.1182/blood-2022-165209

Published: 2022

Journal Articles

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Karan Chohan, Jonas Paludo, Surendra Dasari, Jithma P. Abeykoon, Prashant Kapoor, Esteban Braggio, Michelle K. Manske, Aneel Paulus, Craig B. Reeder, Sikander Ailawadhi, Asher Chanan-Khan, Robert A. Kyle, Morie A Gertz, Anne J. Novak, Stephen M. Ansell

Blood (2022) 140 (Supplement 1): 9242–9243.

https://doi.org/10.1182/blood-2022-167543

Published: 2022

Journal Articles

Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients

Meghna Ailawadhi, MD, Mays F Abdulazeez, MBBS, Leyla Bojanini Molina, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140390

Published: 2020

Journal Articles

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Sikander Ailawadhi, MD, Meghna Ailawadhi, MD, Srilekha Bodepudi, Mays F Abdulazeez, BMSC, Zan Tahir Shareef, Ashna Grover, Maria J Fernandez, Winston Tan, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 411.

https://doi.org/10.1182/blood-2019-125722

Published: 2019

Journal Articles

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Vivek Kumar, MD, M.B.,B.S., Meghna Ailawadhi, MD, Mays F Abdulazeez, MBBS, Suman Biswas, MD, Sri Lekha Bodepudi, Leyla Bojanini, MD, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 4779.

https://doi.org/10.1182/blood-2019-125156

Published: 2019

Journal Articles

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

Vivek Kumar, MD, M.B.,B.S., Mays F Abdulazeez, BMSC, Suman Biswas, MD, Sri Lekha Bodepudi, Vivek Roy, MD, Taimur Sher, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Salman Ahmed, MD, Prachi Jani, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 71.

https://doi.org/10.1182/blood-2019-124799

Published: 2019

Journal Articles

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Jonas Paludo, MD, Surendra Dasari, PhD, Kerstin Wenzl, PhD, Shahrzad Jalali, PhD, Jordan Krull, Michelle Manske, MS, BS, Esteban Braggio, PhD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, MD, Craig B. Reeder, MD, Allison C. Rosenthal, DO, Robert A. Kyle, MD, Morie A Gertz, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2774.

https://doi.org/10.1182/blood-2019-128912

Published: 2019

Journal Articles

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Aneel Paulus, MD, Victoria R. Alegria, Betsy Laplant, MS, Muhamad Alhaj Moustafa, MD, Dustin Chapin, Keisha Jackson, Prachi Jani, MD, Salman Ahmed, MD, Brett Edwards, Alak Manna, PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 1912.

https://doi.org/10.1182/blood-2019-128233

Published: 2019

Journal Articles

Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes

Vivek Kumar, MD, M.B.,B.S., Mays F Abdulazeez, MBBS, Srilekha Bodepudi, Suman Biswas, Vivek Roy, MD, Taimur Sher, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 3494.

https://doi.org/10.1182/blood-2019-125888

Published: 2019

Journal Articles

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Victoria R. Alegria, Salman Ahmed, MD, Betsy Laplant, MS, Alak Manna, PhD, Ricardo Parrondo, MD, Vivek Roy, MD, Taimur Sher, MD, Brett Edwards, Stephanie Lanier, Keisha Jackson, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2019) 134 (Supplement_1): 3137.

https://doi.org/10.1182/blood-2019-128610

Published: 2019

Journal Articles

Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)

Jonas Paludo, MD, Jose Villasboas Bisneto, MD, Anne J Novak, PhD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Esteban Braggio, PhD, Craig B. Reeder, MD, Shahrzad Jalali, PhD, Francis K. Buadi, MB, CHB, Robert A. Kyle, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 4138.

https://doi.org/10.1182/blood-2018-99-117568

Published: 2018

Journal Articles

Depth of Response in Waldenstrom Macroglobulinemia

Jonas Paludo, MD, Jithma Prasad Abeykoon, MD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Craig B. Reeder, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Anne J Novak, PhD, Francis K. Buadi, MB, CHB, Angela Dispenzieri, MD, Yi Lin, MD PhD, Ronald S. Go, MD, Martha Q. Lacy, MD, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Robert A. Kyle, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 4141.

https://doi.org/10.1182/blood-2018-99-111540

Published: 2018

Journal Articles

Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia

Jonas Paludo, MD, Jithma Prasad Abeykoon, MD, Stephen M. Ansell, MD PhD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Craig B. Reeder, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Anne J Novak, PhD, Francis K. Buadi, MB, CHB, Angela Dispenzieri, MD, Yi Lin, MD PhD, Martha Q. Lacy, MD, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Robert A. Kyle, MD, Ronald S. Go, MD

Blood (2018) 132 (Supplement 1): 622.

https://doi.org/10.1182/blood-2018-99-111517

Published: 2018

Journal Articles

Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo

Madiha Iqbal, MBBS, Aarushi Sharma, Alak Manna, PhD, Sharoon Akhtar, MPhil, Taimur Sher, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, Aneel Paulus, MD

Blood (2018) 132 (Supplement 1): 5558.

https://doi.org/10.1182/blood-2018-99-120188

Published: 2018

Journal Articles

Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes

Madiha Iqbal, MBBS, Aaron C. Spaulding, Salman Ahmed, MD, Prachi Jani, MD, Chanel Wood, Shehzad Niazi, Rami Manochakian, MD, Aneel Paulus, MD, Ernesto Ayala, MD, Mohamed A Kharfan-Dabaja, MD, Vivek Roy, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, Taimur Sher, MD

Blood (2018) 132 (Supplement 1): 5873.

https://doi.org/10.1182/blood-2018-99-119781

Published: 2018

NARROW

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)

Depth of Response in Waldenstrom Macroglobulinemia

Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia

Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo

Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only